• News & Media
  • Contact
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Grants & Funding
    • Investigator Sponsored Studies
    • Compliance Declaration
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Menin Inhibition
    • Farnesyl Transferase Inhibitors
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Our Medicine
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • News & Media
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Awards

Kura Makes Fast Company’s 100 Best Workplaces for Innovators List

Kura is proud and honored to be named one of Fast Company’s 2024 100 Best Workplaces for Innovators. We were additionally named to the list of Best Workplaces for Innovators in Biotech.

Across all of our teams, we foster and support outside-the-box thinking that leads to our team members feeling a sense ownership over their work and ability to drive innovation.

Being named to this list alongside leaders in all fields goes to show that Kura’s work for patients is novel through our innovative approaches.

Read more from Fast Company here.

Read more from Chief Operating Officer Kathy Ford here.

If you’re interested in joining our team, learn more about our culture and open positions on our Careers Page.

Back to News & Media
  • About Us
  • Our Commitment
  • The Story Behind Our Name
  • Leadership
  • Board of Directors
  • Grants & Funding
  • Investigator Sponsored Studies
  • Compliance Declaration
  • Our Approach
  • Precision Medicines
  • Overcoming Resistance
  • Novel Biomarkers
  • Pipeline
  • Menin Inhibition
  • Farnesyl Transferase Inhibitors
  • Posters and Presentations
  • Scientific Manuscripts
  • Access to Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
  • Acute Leukemias
  • Head & Neck Cancer
  • Our Medicine
  • Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Analyst Coverage
  • FAQs
  • Contact
  • Careers
  • Values
  • Life at Kura
  • Benefits
  • Open Positions
  • News & Media
  • Press Releases
  • News & Perspectives
  • Expert Perspectives
  • Media Resources
  • Contact

Kura Oncology, Inc.
4930 Directors Place, Suite 500
San Diego, CA 92121
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

© 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy | Cookie Policy | Consumer Health Data

Scroll to top Scroll to top Scroll to top